An orally bioavailable drug for treating Non-Alchoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD). NASH often predisposes development of fibrosis and cancer and it is the fastest growing cause of liver disease in the USA and Europe. 2.4 Billion people are affected by these diseases worldwide each year. MTI-301 is a rate limiting lipogenic enzyme that catalyzes the synthesis of Δ-9-monounsaturated fatty acids, oleate and palmitoleic acid in the liver resulting in reduced diet-induced liver steatosis and obesity while also improving insulin sensitivity.
MTI-301-C is a novel SCD-1 Inhibitor for treating Cancer. Convincing pre-clinical activity has been demonstrated in Breast and HepatoCellular Cancer with tolerable off target effects. MTI-301-C is expected to to be available in a Phase I trail before the end of 2023. This orally bioavailable drug limits the conversion of saturated fatty acids to Mono-Unsatured Fatty Acids, which is upregulated and required by cancer cells for survival.